MX2024001417A - Compuestos de heteroarilo para tratar la enfermedad de huntington. - Google Patents
Compuestos de heteroarilo para tratar la enfermedad de huntington.Info
- Publication number
- MX2024001417A MX2024001417A MX2024001417A MX2024001417A MX2024001417A MX 2024001417 A MX2024001417 A MX 2024001417A MX 2024001417 A MX2024001417 A MX 2024001417A MX 2024001417 A MX2024001417 A MX 2024001417A MX 2024001417 A MX2024001417 A MX 2024001417A
- Authority
- MX
- Mexico
- Prior art keywords
- disease
- compounds
- heteroaryl compounds
- treating huntington
- forms
- Prior art date
Links
- 208000023105 Huntington disease Diseases 0.000 title abstract 3
- 125000001072 heteroaryl group Chemical group 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 239000000203 mixture Substances 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163203761P | 2021-07-30 | 2021-07-30 | |
| PCT/US2022/038870 WO2023009816A1 (en) | 2021-07-30 | 2022-07-29 | Heteroaryl compounds for treating huntington's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024001417A true MX2024001417A (es) | 2024-05-14 |
Family
ID=83149486
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024001417A MX2024001417A (es) | 2021-07-30 | 2022-07-29 | Compuestos de heteroarilo para tratar la enfermedad de huntington. |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20240336613A1 (enExample) |
| EP (1) | EP4377317A1 (enExample) |
| JP (1) | JP2024528066A (enExample) |
| KR (1) | KR20240054264A (enExample) |
| CN (1) | CN118159539A (enExample) |
| AR (1) | AR126612A1 (enExample) |
| AU (1) | AU2022320725A1 (enExample) |
| CA (1) | CA3227287A1 (enExample) |
| CL (1) | CL2024000250A1 (enExample) |
| CO (1) | CO2024000890A2 (enExample) |
| CR (1) | CR20240043A (enExample) |
| IL (1) | IL310440A (enExample) |
| MX (1) | MX2024001417A (enExample) |
| PE (1) | PE20240929A1 (enExample) |
| TW (1) | TW202321247A (enExample) |
| WO (1) | WO2023009816A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018282154B2 (en) | 2017-06-05 | 2022-04-07 | Ptc Therapeutics, Inc. | Compounds for treating huntington's disease |
| AU2019243048A1 (en) | 2018-03-27 | 2020-10-15 | Ptc Therapeutics, Inc. | Compounds for treating Huntington's disease |
| IL279688B2 (en) | 2018-06-27 | 2025-01-01 | Ptc Therapeutics Inc | Heterocyclic and heteroaryl compounds for the treatment of Huntington's disease |
| BR112020026534A2 (pt) | 2018-06-27 | 2021-03-23 | Ptc Therapeutics, Inc. | Compostos de heteroarila para o tratamento da doença de huntington |
| CN114245794B (zh) | 2019-05-13 | 2024-09-13 | Ptc医疗公司 | 用于治疗亨廷顿氏病的化合物 |
| CN119451674A (zh) * | 2022-06-15 | 2025-02-14 | Ptc医疗公司 | 用于治疗亨廷顿病的杂环和杂芳基化合物 |
| EP4719599A1 (en) | 2023-06-02 | 2026-04-08 | Merck Sharp & Dohme LLC | 5,6 unsaturated bicyclic heterocyles useful as inhibitors of nod-like receptor protein 3 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL279688B2 (en) * | 2018-06-27 | 2025-01-01 | Ptc Therapeutics Inc | Heterocyclic and heteroaryl compounds for the treatment of Huntington's disease |
| WO2020005882A1 (en) * | 2018-06-27 | 2020-01-02 | Ptc Therapeutics, Inc. | Heteroaryl compounds for treating huntington's disease |
| JP2022525417A (ja) * | 2019-03-15 | 2022-05-13 | スカイホーク・セラピューティクス・インコーポレーテッド | 異常スプライシングを修正するための組成物および方法 |
-
2022
- 2022-07-29 WO PCT/US2022/038870 patent/WO2023009816A1/en not_active Ceased
- 2022-07-29 CR CR20240043A patent/CR20240043A/es unknown
- 2022-07-29 AR ARP220102027A patent/AR126612A1/es unknown
- 2022-07-29 AU AU2022320725A patent/AU2022320725A1/en active Pending
- 2022-07-29 JP JP2024505314A patent/JP2024528066A/ja active Pending
- 2022-07-29 US US18/293,349 patent/US20240336613A1/en active Pending
- 2022-07-29 EP EP22761694.3A patent/EP4377317A1/en active Pending
- 2022-07-29 CA CA3227287A patent/CA3227287A1/en active Pending
- 2022-07-29 KR KR1020247003414A patent/KR20240054264A/ko active Pending
- 2022-07-29 PE PE2024000170A patent/PE20240929A1/es unknown
- 2022-07-29 IL IL310440A patent/IL310440A/en unknown
- 2022-07-29 MX MX2024001417A patent/MX2024001417A/es unknown
- 2022-07-29 CN CN202280066651.3A patent/CN118159539A/zh active Pending
- 2022-08-01 TW TW111128808A patent/TW202321247A/zh unknown
-
2024
- 2024-01-29 CL CL2024000250A patent/CL2024000250A1/es unknown
- 2024-01-30 CO CONC2024/0000890A patent/CO2024000890A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3227287A1 (en) | 2023-02-02 |
| TW202321247A (zh) | 2023-06-01 |
| KR20240054264A (ko) | 2024-04-25 |
| US20240336613A1 (en) | 2024-10-10 |
| CR20240043A (es) | 2024-05-22 |
| WO2023009816A1 (en) | 2023-02-02 |
| AR126612A1 (es) | 2023-10-25 |
| CL2024000250A1 (es) | 2024-07-12 |
| AU2022320725A1 (en) | 2024-02-22 |
| IL310440A (en) | 2024-03-01 |
| JP2024528066A (ja) | 2024-07-26 |
| CO2024000890A2 (es) | 2024-04-29 |
| PE20240929A1 (es) | 2024-04-30 |
| EP4377317A1 (en) | 2024-06-05 |
| CN118159539A (zh) | 2024-06-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020009957A (es) | Compuestos para el tratamiento de enfermedad de hungtinton. | |
| MX2020014315A (es) | Compuestos de heteroarilo para tratar la enfermedad de huntington. | |
| ZA202100208B (en) | Heterocyclic and heteroaryl compounds for treating huntington's disease | |
| CR20240043A (es) | Compuestos de heteroarilo para tratar la enfermedad de huntington | |
| WO2018226622A8 (en) | Compounds for treating huntington's disease | |
| ZA202403923B (en) | Heterocyclic compounds as immunomodulators | |
| MX2021001091A (es) | Compuestos para usarse en el tratamiento o mejoramiento de la enfermedad de huntington. | |
| MX2019015580A (es) | Metodos para tratar la enfermedad de huntington. | |
| MX2019015578A (es) | Metodos para tratar la enfermedad de huntington. | |
| MX2024014435A (es) | Compuestos heterociclicos y heteroarilo para el tratamiento de la enfermedad de huntington | |
| MX2022001690A (es) | Compuestos deuterados para usarse en el tratamiento del cancer. | |
| MX2019011530A (es) | Saxitoxinas 11,13-modificadas para el tratamiento del dolor. | |
| SG146648A1 (en) | Pharmaceutical compositions for treating premature ejaculation by pulmonary inhalation | |
| MX389965B (es) | Compuestos de pirrolopiridina-anilina para el tratamiento de trastornos dermicos | |
| PH12021500034A1 (en) | Compounds useful in hiv therapy | |
| PH12021551304A1 (en) | Tyrosine kinase inhibitors, compositions and methods there of | |
| MX2023001296A (es) | Composiciones y metodos para tratar enfermedades y trastornos. | |
| SE9903894D0 (sv) | Novel compounds | |
| MX2024002131A (es) | Inhibidores de la 17-beta-hidroxisteroide deshidrogenasa tipo 13 y metodos de uso de los mismos. | |
| ZA202400821B (en) | Inhibitors of transglutaminases | |
| MX2023009166A (es) | Derivados de quinoxalina y sus usos. | |
| ZA202211253B (en) | Compositions comprising 15-hepe for treating or preventing hematologic disorders, and/or related diseases | |
| MX2024014831A (es) | Derivados de acido sialico y metodos de uso de los mismos | |
| MX2025003004A (es) | Formas farmaceuticas de un inhibidor de cd73 | |
| EP4620940A3 (en) | Synthesis of (+)-cannabinoids and their therapeutic effects |